Medical Costs and Outcomes for Australian Women With Ovarian Cancer
Louisa G. Gordon(Queensland University of Technology), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Anna DeFazio(The University of Sydney), David Wyld(QIMR Berghofer Medical Research Institute), Adèle C. Green(QIMR Berghofer Medical Research Institute), Paul Scuffham(Griffith University), Alexandra Clavarino, Vanessa L. Beesley(QIMR Berghofer Medical Research Institute)
Cited by 24
Related Papers
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
|Nature Genetics|1994|850
Driver mutations in <i>TP53</i> are ubiquitous in high grade serous carcinoma of the ovary
|The Journal of Pathology|2010|836
Type I and II Endometrial Cancers: Have They Different Risk Factors?
|Journal of Clinical Oncology|2013|833